Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1982 1
1983 5
1984 2
1985 16
1986 17
1987 14
1988 27
1989 19
1990 28
1991 25
1992 28
1993 19
1994 24
1995 28
1996 25
1997 28
1998 25
1999 26
2000 30
2001 24
2002 26
2003 20
2004 24
2005 18
2006 30
2007 40
2008 32
2009 28
2010 24
2011 39
2012 29
2013 31
2014 32
2015 44
2016 38
2017 35
2018 40
2019 30
2020 16
2021 12
Text availability
Article attribute
Article type
Publication date

Search Results

933 results
Results by year
Filters applied: . Clear all
Page 1
Refractory ventricular fibrillation treated with esmolol.
Lee YH, Lee KJ, Min YH, Ahn HC, Sohn YD, Lee WW, Oh YT, Cho GC, Seo JY, Shin DH, Park SO, Park SM. Lee YH, et al. Resuscitation. 2016 Oct;107:150-5. doi: 10.1016/j.resuscitation.2016.07.243. Epub 2016 Aug 11. Resuscitation. 2016. PMID: 27523955
RESULTS: Twenty-five patients did not receive esmolol (the control group), and 16 patients received esmolol. Sustained return of spontaneous circulation (ROSC) was significantly more common in the esmolol group, compared to the control group (56% vs. 16%, p=0 …
RESULTS: Twenty-five patients did not receive esmolol (the control group), and 16 patients received esmolol. Sustained return …
Effect of heart rate control with esmolol on hemodynamic and clinical outcomes in patients with septic shock: a randomized clinical trial.
Morelli A, Ertmer C, Westphal M, Rehberg S, Kampmeier T, Ligges S, Orecchioni A, D'Egidio A, D'Ippoliti F, Raffone C, Venditti M, Guarracino F, Girardis M, Tritapepe L, Pietropaoli P, Mebazaa A, Singer M. Morelli A, et al. JAMA. 2013 Oct 23;310(16):1683-91. doi: 10.1001/jama.2013.278477. JAMA. 2013. PMID: 24108526 Clinical Trial.
For stroke volume index, the median AUC for esmolol was 4 mL/m2 (IQR, -1 to 10) vs 1 mL/m2 for the control group (IQR, -3 to 5; P = .02), whereas the left ventricular stroke work index for esmolol was 3 mL/m2 (IQR, 0 to 8) vs 1 mL/m2 for the control group (IQR, -2 t …
For stroke volume index, the median AUC for esmolol was 4 mL/m2 (IQR, -1 to 10) vs 1 mL/m2 for the control group (IQR, -3 to 5; P = . …
Esmolol.
O'Flaherty D. O'Flaherty D. Can J Anaesth. 1993 Jul;40(7):687-8. doi: 10.1007/BF03009720. Can J Anaesth. 1993. PMID: 8104725 No abstract available.
Efficacy of esmolol cardioplegia during hypothermic ischaemia.
Nishina D, Chambers DJ. Nishina D, et al. Eur J Cardiothorac Surg. 2018 Feb 1;53(2):392-399. doi: 10.1093/ejcts/ezx311. Eur J Cardiothorac Surg. 2018. PMID: 28958063
A further study examined the protective efficacy of multidose esmolol cardioplegia compared with hypothermia alone at temperatures of 20C, 28C and 32C compared with 37C for 120 min of ischaemia. ...At various hypothermic temperatures, esmolol cardioplegia significan …
A further study examined the protective efficacy of multidose esmolol cardioplegia compared with hypothermia alone at temperatures of …
Esmolol, Antinociception, and Its Potential Opioid-Sparing Role in Routine Anesthesia Care.
Bahr MP, Williams BA. Bahr MP, et al. Reg Anesth Pain Med. 2018 Nov;43(8):815-818. doi: 10.1097/AAP.0000000000000873. Reg Anesth Pain Med. 2018. PMID: 30216240 Review.
Esmolol, to date, has not shown any direct analgesic or anesthetic properties; however, recent studies suggest that esmolol may have antinociceptive and postoperative opioid-sparing effects. In this Daring Discourse narrative, we describe the role of esmolol
Esmolol, to date, has not shown any direct analgesic or anesthetic properties; however, recent studies suggest that esmolol ma
Esmolol. A review of its therapeutic efficacy and pharmacokinetic characteristics.
Wiest D. Wiest D. Clin Pharmacokinet. 1995 Mar;28(3):190-202. doi: 10.2165/00003088-199528030-00002. Clin Pharmacokinet. 1995. PMID: 7758250 Review.
Esmolol is an ultra short-acting intravenous cardioselective beta-antagonist. ...The elimination of esmolol is independent of renal or hepatic function as it is metabolised by red blood cell cytosol esterases to an acid metabolite and methanol. ...
Esmolol is an ultra short-acting intravenous cardioselective beta-antagonist. ...The elimination of esmolol is independent of
Perioperative use of esmolol.
Reves JG, Flezzani P. Reves JG, et al. Am J Cardiol. 1985 Oct 23;56(11):57F-62F. doi: 10.1016/0002-9149(85)90917-8. Am J Cardiol. 1985. PMID: 2864850 Review.
With esmolol treatment, the difficulties of therapy with long-lasting beta blockers are avoided. ...Clinical studies performed during the perioperative period reveal that esmolol is safe and effective in this setting. Esmolol has been shown to be safe and eff …
With esmolol treatment, the difficulties of therapy with long-lasting beta blockers are avoided. ...Clinical studies performed during …
Dose-dependent Effects of Esmolol-epinephrine Combination Therapy in Myocardial Ischemia and Reperfusion Injury.
Oyama Y, Blaskowsky J, Eckle T. Oyama Y, et al. Curr Pharm Des. 2019;25(19):2199-2206. doi: 10.2174/1381612825666190618124829. Curr Pharm Des. 2019. PMID: 31258066 Free PMC article.
Increasing the esmolol dose, however, was able to restore esmolol-cardioprotection in the epinephrine-esmolol (18.68% infarct size) co-treatment group with improved hemodynamics compared to the esmolol group (epinephrine-esmolol vs. esmolol
Increasing the esmolol dose, however, was able to restore esmolol-cardioprotection in the epinephrine-esmolol (18.68% i …
Clinical pharmacokinetics and therapeutic efficacy of esmolol.
Wiest DB, Haney JS. Wiest DB, et al. Clin Pharmacokinet. 2012 Jun 1;51(6):347-56. doi: 10.2165/11631590-000000000-00000. Clin Pharmacokinet. 2012. PMID: 22515557 Review.
Esmolol is a unique cardioselective beta(1)-receptor blocking agent with a rapid onset and short duration of action. ...For postoperative patients in atrial fibrillation, esmolol achieves rapid ventricular rate control. However, for the prevention of postoperative a
Esmolol is a unique cardioselective beta(1)-receptor blocking agent with a rapid onset and short duration of action. ...For postopera
Esmolol: a review of its use in the short-term treatment of tachyarrhythmias and the short-term control of tachycardia and hypertension.
Garnock-Jones KP. Garnock-Jones KP. Drugs. 2012 Jan 1;72(1):109-32. doi: 10.2165/11208210-000000000-00000. Drugs. 2012. PMID: 22191799 Review.
Esmolol is, moreover, generally well tolerated; while it is associated with an increased risk of hypotension, this is rapidly reversible. Definitive conclusions on the efficacy of esmolol are difficult to reach, as most trials investigating esmolol have limit
Esmolol is, moreover, generally well tolerated; while it is associated with an increased risk of hypotension, this is rapidly reversi
933 results